blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP0552031

EP0552031 - Oxepane isomers of rapamycin useful as immunosuppressive agents [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  13.11.2009
Database last updated on 23.04.2024
Most recent event   Tooltip09.04.2010Lapse of the patent in a contracting state
New state(s): CH, LI
published on 12.05.2010  [2010/19]
Applicant(s)For all designated states
Wyeth
Five Giralda Farms
Madison, NJ 07940-0874 / US
[N/P]
Former [2002/25]For all designated states
Wyeth
Five Giralda Farms
Madison, New Jersey 07940-0874 / US
Former [1993/29]For all designated states
AMERICAN HOME PRODUCTS CORPORATION
Five Giralda Farms
Madison, New Jersey 07940-0874 / US
Inventor(s)01 / Hughes, Philip Floyd
627 Arlington Street, Chapel Hill
Orange County, North Carolina 27514 / US
[1993/29]
Representative(s)Wileman, David Francis, et al
C/o Wyeth Laboratories Huntercombe Lane South Taplow Maidenhead
Berkshire SL6 OPH / GB
[N/P]
Former [1993/29]Wileman, David Francis, Dr., et al
c/o Wyeth Laboratories Huntercombe Lane South
Taplow Maidenhead Berkshire SL6 OPH / GB
Application number, filing date93300207.314.01.1993
[1993/29]
Priority number, dateUS1992082217116.01.1992         Original published format: US 822171
[1993/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP0552031
Date:21.07.1993
Language:EN
[1993/29]
Type: B1 Patent specification 
No.:EP0552031
Date:12.06.2002
Language:EN
[2002/24]
Search report(s)(Supplementary) European search report - dispatched on:EP04.05.1993
ClassificationIPC:C07D498/18, A61K31/435, // (C07D498/18, 313:00, 273:00, 273:00)
[1993/29]
CPC:
C07D471/18 (EP,US); A61P29/00 (EP); A61P31/12 (EP);
A61P31/14 (EP); A61P37/06 (EP)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [1993/29]
TitleGerman:Oxepan-Isomere von Rapamycin brauchbar als immunosuppressive Wirkstoffe[1993/29]
English:Oxepane isomers of rapamycin useful as immunosuppressive agents[1993/29]
French:Isomères oxépaniques de rapamycine utiles comme agents immunosuppresseurs[1993/29]
Examination procedure23.11.1993Examination requested  [1994/03]
07.05.1997Despatch of a communication from the examining division (Time limit: M08)
23.04.1998Reply to a communication from the examining division
01.06.1999Despatch of a communication from the examining division (Time limit: M06)
07.01.2000Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.03.2000Reply to a communication from the examining division
20.12.2000Despatch of a communication from the examining division (Time limit: M04)
30.04.2001Reply to a communication from the examining division
13.08.2001Despatch of communication of intention to grant (Approval: Yes)
13.12.2001Communication of intention to grant the patent
04.03.2002Fee for grant paid
04.03.2002Fee for publishing/printing paid
Opposition(s)Opponent(s)01  12.03.2003    ADMISSIBLE
ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park IL 60064 / US
Opponent's representative
Wright, Robert Gordon McRae
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks
Kent TN13 1XR / GB
 [N/P]
Former [2003/19]
Opponent(s)01  12.03.2003    ADMISSIBLE
Abbott Laboratories
100 Abbott Park Road, Abbott Park
Illinois 60064-6050 / US
Opponent's representative
Wright, Robert Gordon McRae
Elkington & Fife, Prospect House, 8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
22.04.2003Invitation to proprietor to file observations on the notice of opposition
02.01.2004Reply of patent proprietor to notice(s) of opposition
05.02.2007Date of oral proceedings
07.05.2007Despatch of minutes of oral proceedings
07.05.2007Despatch of communication that the patent will be revoked
16.10.2009Legal effect of revocation of patent [2009/51]
Appeal following opposition02.07.2007Appeal received No.  T1103/07
12.09.2007Statement of grounds filed
16.10.2009Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:10.03.2000Request for further processing filed
10.03.2000Full payment received (date of receipt of payment)
Request granted
28.03.2000Decision despatched
23.04.1998Request for further processing filed
23.04.1998Full payment received (date of receipt of payment)
Request deemed not to be filed
11.05.1998Decision despatched
Fees paidRenewal fee
18.11.1994Renewal fee patent year 03
16.11.1995Renewal fee patent year 04
18.11.1996Renewal fee patent year 05
17.11.1997Renewal fee patent year 06
18.11.1998Renewal fee patent year 07
27.12.1999Renewal fee patent year 08
05.01.2001Renewal fee patent year 09
10.01.2002Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH12.06.2002
LI12.06.2002
AT14.01.2008
BE31.01.2008
PT14.07.2008
GR04.08.2008
[2010/19]
Former [2009/30]AT14.01.2008
BE31.01.2008
PT14.07.2008
GR04.08.2008
Former [2009/14]AT14.01.2008
BE31.01.2008
PT14.07.2008
Former [2008/49]AT14.01.2008
PT14.07.2008
Documents cited:SearchGB2246350  [ ] (FUJISAWA PHARMACEUTICAL CO [JP]);
    [ ] - D. ASKIN ET AL., "Chemistry of FK-506: Benzilic acid rearrangement of the tricarbonyl system", TETRAHEDRON LETTERS, (1989), vol. 30, no. 6, pages 671 - 674, XP003012927

DOI:   http://dx.doi.org/10.1016/S0040-4039(01)80278-1
    [ ] - HUGHES P. ET AL., "The isolation, synthesis and characterization of an isomeric form of rapamycin", TETRAHEDRON LETTERS, (1992), vol. 33, no. 33, pages 4739 - 4742, XP002436593

DOI:   http://dx.doi.org/10.1016/S0040-4039(00)61273-X
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.